(Formerly known as: 康誠工程科技有限公司) is a wholly-owned subsidiary invested by HealthConnex under the Foxconn Technology Group, with molecular genetics and functional medical testing as its primary service offerings. It actively cooperates and exchanges with domestic and international molecular biotechnology partners, and based on functional medical testing technology, actively expands its applications in molecular genetics. In molecular genetic testing technology, the company has repeatedly won the trust and cooperation of international biotechnology companies, obtaining the exclusive distributorship in Taiwan for Guardant Health, a well-known American cancer liquid biopsy company, to provide Guardant360 testing services for advanced cancer patients, identifying mutated genes in tumor cells upon cancer recurrence to evaluate the best treatment options. In addition to introducing global cutting-edge technologies, the company also continuously launches gene testing solutions for tumor tissues and liquid biopsies through the research and development of its own cancer gene testing products, focusing on the clinical diagnosis, recurrence assessment, and follow-up of lung cancer and colorectal cancer, thereby assisting clinicians in making the most beneficial medical decisions for cancer patients. Leveraging the broad and deep global layout capabilities of the Foxconn Group, the company moves toward preventing diseases before they occur, starting from testing and extending to customized monitoring, risk assessment, and big data integration. In the future, it will collaborate with major international biotechnology companies to develop early cancer diagnosis and testing, develop companion diagnostic technologies, and develop testing platforms with Chinese gene specificity.